Magnetic Resonance-guided High Intensity Focused Ultrasound for Palliation of Painful Skeletal Metastases - a Multicenter Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Bone Metastasis
- Sponsor
- Philips Healthcare
- Enrollment
- 20
- Locations
- 3
- Primary Endpoint
- Pain response to therapy
- Status
- Terminated
- Last Updated
- 9 years ago
Overview
Brief Summary
The purpose of this study is to evaluate the effectiveness of the Philips Sonalleve Magnetic Resonance Imaging-guided High Intensity Focused Ultrasound (MR-HIFU) device for treating painful bone metastases.
Detailed Description
Magnetic Resonance Imaging-guided High Intensity Focused Ultrasound (MR-HIFU) is a non-invasive outpatient modality. In MR-HIFU, a specially designed ultrasound transducer is used to focus a beam of ultrasound energy into a small volume at a specific target site in the body. The focused beam is intended to produce therapeutic hyperthermia in the target field while only harmlessly warming the immediately surrounding tissue. Magnetic Resonance Imaging is used during the ultrasound treatment, both to focus the ultrasound beam on the target field and to perform real-time thermal mapping at and around the target. The Philips Sonalleve MR-HIFU system is expected to be efficacious in reducing pain scores in patients with painful bone metastases and in reducing their pain medication usage.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Men and women with age ≥ 18 years
- •Patient capable of giving informed consent and able to attend study visits
- •Weight \< 140kg
- •Radiologic evidence of bone metastases from any solid tumor
- •Diagnosis of dominant painful bone metastasis (Numerical Representative Scale (NRS) pain score ≥4), either refractory to standard of care (including radiotherapy and optimal pain medication) or standard of care is contra-indicated or refused by patient.
- •Patient has been on stable pain medication for at least 1 week prior to HIFU treatment date
- •Pain is localized to the targeted area, or is likely to be referred pain arising from the targeted area
- •Patient has 1-3 painful lesions, and only the most painful lesion will be treated
- •Intended Target Volume accessible for MR-HIFU procedure
- •Target lesion maximum dimension ≤ 8cm
Exclusion Criteria
- •Planned treatment lesion is a primary bone tumor or due to lymphoma, multiple myeloma, or leukemia.
- •Communication barrier present
- •Patient enrolled in another clinical study related to bone metastases treatment or pain relief treatment
- •Unable to tolerate required stationary position during treatment
- •Need for surgical stabilization in case of (impending) fracture (lytic lesion in weight-bearing bone larger than 50% of bone diameter)
- •Pregnant woman
- •Pain related to target lesion is predominantly due to fracture or impending fracture
- •Pain related to target lesion is due to involvement of a neighboring major nerve by the metastatic tumor (cord or nerve compression)
- •Target \< 3cm from bladder / bowel / nerve along the beam path and \< 1cm in the plane orthogonal to the beam
- •Target in contact with hollow viscera
Outcomes
Primary Outcomes
Pain response to therapy
Time Frame: 30 days after treatment
Pain is measured using the Brief Pain Inventory (BPI) questionnaire. Patients are categorized into: * Complete response (CR): Pain score 0 without analgesic increase * Partial response (PR): Pain reduction of 2 or more without analgesic increase; or analgesic reduction of 25% without pain increase * Pain Progression (PP): Pain increase of 2 or more with stable analgesic use; or increase of 25% or more in analgesic use, with pain score stable or 1 point above baseline * No response corresponds to all other cases Patients with PR or CR at 30 days are considered responders to therapy.
Secondary Outcomes
- Temporal evolution of pain response during the first 30 days after treatment(during the first 30 days after treatment)
- Total number of Adverse Events(within the first 90 days within treatment)
- Quality of Life (as measured by questionnaire)(at day 0 before treatment, and at 7, 14, 30, 60 and 90 days after treatment)
- Subgroup analysis: pain response in radiation naïve patients(30 days after treatment)